ESMO WCGIC 2021 | Monitoring MRD by ctDNA in resectable CRC

Hiromichi Shirasu, MD, Shizuoka Cancer Center, Shizuoka, Japan, discusses findings of a molecular subgroup analysis of the CIRCULATE-Japan study, identifying molecular residual disease (MRD) using circulating tumor DNA (ctDNA) analysis in patients with resectable colorectal cancer (CRC). In this subgroup analysis, an association between ctDNA-based MRD status and tissue biomarkers were observed, suggesting the ctDNA potential for reflecting biological aggressiveness related to biomarkers. However, further investigations are needed. This interview took place at the ESMO World Congress on Gastrointestinal Cancer 2021.